Abstract

Neutrophil gelatinase-associated lipocalin, known also as 24p3 lipocalin, lipocalin-2 or uterocalin (in mouse), is a small secretory protein binding small molecular weight ligands which takes part in numerous processes including apoptosis induction in leukocytes, iron transport, smell, and prostaglandins and retinol transport [19]. It was discovered in activated neutrophils as a covalent peptide associated with human gelatinase neutrophils [7]. Neutrophil lipocalin is secreted physiologically in the digestive system, respiratory tract, renal tubular cells, liver or immunity system. Systematic (circulated in plasma) neutrophil gelatinase come from multiple sources; it may be synthesized in the liver, secreted from activated neutrophils or macrophages, or derive from atherosclerosis or inflammatory endothelial cells [17]. NGAL is stored secondarily in granulates with lactoferrin, calprotectin or MAC-1, which take part in neutrophils’ action and migration [13,19]. NGAL participates in acute and chronic inflammation (production of NGAL is indicated by factors conducive to cancer progression) [13,21]. NGAL levels increase in inflammatory or endothelial damage. NGAL level is measured in blood or urine. It is known as a kidney failure factor [7,20]. NGAL is therefore one of the most promising new generation biomarkers in clinical nephrology [6]. The role of NGAL in digestive system neoplasms has not been explored in detail. However, overexpression of this marker was proved in neoplasms such as esophageal carcinoma, stomach cancer, pancreatic cancer or colon cancer, which may indicate an association between concentration and neoplasm [3].

References

• 1. Baressi V., Luciano R., Vitarelli E., Labate A., Tuccari G., BarresiG.: Neutrophil gelatinase-associated lipocalin immunoexpressionin colorectal carcinoma: a stage-specific prognostic factor? Oncol.Lett., 2010; 1: 1089-1096
  Google Scholar
• 2. Budzyńska A., Nowakowska-Dulawa E., Marek T., Boldys H., NowakA., Hartleb M.: Differentation of pancreatobiliary cancer frombenign biliary strictures using neutrophil gelatinase-associated lipocalin.J. Physiol. Pharmacol., 2013; 64: 109-114
  Google Scholar
• 3. Candido S., Maestro R., Polesel J., Catania A., Maira F., SignorelliS.S., McCubrey J.A., Libra M.: Roles of neutrophil gelatinase-associatedlipocalin (NGAL) in human cancer. Oncotarget, 2014; 5: 1576-1594
  Google Scholar
• 4. Chakraborty S., Kaur S., Guha S., Batra S.K.: The multifaceted rolesof neutrophil gelatinase associated lipocalin (NGAL) in inflammationand cancer. Biochim. Biophys. Acta, 2012; 1826: 129-169
  Google Scholar
• 5. Du Z.P., Lv Z., Wu B.L., Wu Z.Y., Shen J.H., Wu J.Y., Xu X.E., HuangQ., Shen J., Chen H.B., Li E.M., Xu L.Y.: Neutrophil gelatinase-associatedlipocalin and its receptor: independent prognostic factors ofoesophageal squamous cell carcinoma. J. Clin. Pathol., 2011; 64: 69-74
  Google Scholar
• 6. Furutani M., Arii S.: Identification of a neutrophil gelatinase-associatedlipocalin mRNA in human pancreatic cancers using a modifiedsignal sequence trap method. Cancer Lett.,1998; 122: 209-214
  Google Scholar
• 7. Gala-Błądzińska A., Kuźniewski M.: Oznaczanie lipokaliny zwią-zanej z żelatynazą neutrofili (NGAL) w praktyce klinicznej. Przegl.Lek., 2013; 70: 400-403
  Google Scholar
• 8. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., RaymondK.N., Strong R.K.: The neutrophil lipocalin NGAL is a bacteriostaticagent that interferes with siderophore-mediated iron acquisition.Mol. Cell., 2002; 10: 1033-1043
  Google Scholar
• 9. Han H., Bearss D.J., Browne L.W., Calaluce R., Nagle R.B., Von HoffD.D.: Identification of differentially expressed genes in pancreaticcancer cells using cDNA microarray. Cancer Res., 2002; 62: 2890-2896
  Google Scholar
• 10. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen–Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H.: Highly expressed genes in pancreaticductal adenocarcinomas: a comprehensive characterization andcomparison of the transcription profiles obtained from three majortechnologies. Cancer Res., 2003; 63: 8614-8622
  Google Scholar
• 11. Iacobuzio-Donahue C.A., Maitra A., Olsen M., Lowe A.W., vanHeek N.T., Rosty C., Walter K., Sato N., Parker A., Ashfaq R., Jaffee E.,Ryu B., Jones J., Eshleman J.R., Yeo C.J., et al.: Exploration of globalgene expression patterns in pancreatic adenocarcinoma using cDNAmicroarrays. Am. J. Pathol., 2003; 162: 1151-1162
  Google Scholar
• 12. Immunoassays lipocalin-2-ngal-human-elisa. http://www.biovendor.com(02.06.2015)
  Google Scholar
• 13. Lee H.J., Lee E.K.., Lee K.J., Hong S.W., Yoon Y., Kim J.S.: Ectopicexpression of neutrophil gelatinase-associated lipocalin suppressesthe invasion and liver metastasis of colon cancer cells. Int. J. Cancer,2006; 118: 2490-2497
  Google Scholar
• 14. Leelawat K., Narong S., Wannaprasert J., Leelawat S.: SerumNGAL to clinically distinguish cholangiocarcinoma from benign biliarytract diseases. Int. J. Hepatol., 2011; 2011: 873548
  Google Scholar
• 15. Loch J.: Badania strukturalne oddziaływań laktoglobulinyze związkami o działaniu biologicznym. http://www.zbf.wbbib.uj.edu.pl/documents/3312903/68672511/materialy%20ref.1.pdf(20.05.2014)
  Google Scholar
• 16. Moniaux N., Chakraborty S., Yalniz M., Gonzalez J., ShostromV.K., Standop J., Lele S.M., Ouellette M., Pour P.M., Sasson A.R., BrandR.E., Hollingsworth M.A., Jain M., Batra S.K.: Early diagnosis of pancreaticcancer: neutrophil gelatinase-associated lipocalin as a markerof pancreatic intraepithelial neoplasia.. Br. J. Cancer, 2008; 98:1540-1547
  Google Scholar
• 17. Nguyen M.T., Devarajan P.: Biomarkers for the early detection ofacute kidney injury. Pediatric Nephrol., 2008; 23: 2151-2157
  Google Scholar
• 18. Nielsen P.N., Borregaard N., Bundgaard J.R.: Induction of NGALsynthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut, 1996; 38: 414-420
  Google Scholar
• 19. Radosz A., Obuchowicz A.: Potencjalne znaczenie diagnostycznelipokaliny neutrofilowej związanej z żelatynazą. Ann. AcademiaeMed. Silesiensis, 2013; 67: 61-66
  Google Scholar
• 20. Schmidt-Ott K.M., Mori K., Li J.Y., Kalandadze A., Cohen D.J., DevarajanP., Barasch J.: Dual action of neutrophil gelatinase-associatedlipocalin. J. Am. Soc. Nephrol., 2007; 18: 407-413
  Google Scholar
• 21. Singer E., Markó L., Paragas N., Barasch J., Dragun D., MüllerD.N., Budde K., Schmidt-Ott K.M.: Neutrophil gelatinase-associatedlipocalin: pathophysiology and clinical applications. Acta Physiol.,2013; 207: 663-672
  Google Scholar
• 22. Tong Z., Kunnumakkara A.B., Wang H., Matsuo Y., DiagaradjaneP., Harikumar K.B., Ramachandran V., Sung B., Chakraborty A., BresalierR.S., Logsdon C., Aggarwal B.B., Krishnan S., Guha S.: Neutrophilgelatinase-associated lipocalin: a novel suppressor of invasion andangiogenesis in pancreatic cancer. Cancer Res., 2008; 68: 6100-6108
  Google Scholar
• 23. Wang H.J., He X.J., Ma Y.Y., Jiang X.T., Xia Y.J., Ye Z.Y., Zhao Z.S.,Tao H.Q.: Expressions of neutrophil gelatinase-associated lipocalinin gastric cancer: a potential biomarker for prognosis and an ancillarydiagnostic test. Anat. Rec., 2010; 11: 1855-1863
  Google Scholar
• 24. Zabron A., Horneffer-van der Sluis V.M., Wadsworth C.A., LairdF., Gierula M., Thillainayagam A.V., Vlavianos P., Westaby D., Taylor–Robinson S.D., Edwards R.J., Khan S.A.: Elevated levels of neutrophilgelatinase-associated lipocalin in bile from patients with malignantpancreatobiliary disease. Am. J. Gastroenterol., 2011; 106: 1711-1717
  Google Scholar
• 25. Zhang H., Xu L., Xiao D., Xie J., Zeng H., Wang Z., Zhang X., NiuY., Shen Z., Shen J., Wu X., Li E.: Upregulation of neutrophil gelatinase‐associatedlipocalin in oesophageal squamous cell carcinoma:significant correlation with cell differentiation and tumour invasion.J. Clin. Pathol., 2007; 60: 555-561
  Google Scholar

Full text